A. Garvey Rene, MD, FACC, FSCAI — Interventional Cardiology
Heart & Vascular Care

A. Garvey Rene

MD, FACC, FSCAI

Dr. Rene attended Johns Hopkins University where he graduated with Honors. He earned his medical doctorate from the Weill Cornell Medical College in New York City, and went on to complete his residency in internal medicine at Columbia University Medical Center.

Following his training in internal medicine, Dr. Rene went on to complete his general cardiology fellowship at the Hospital of the University of Pennsylvania. He stayed at the University of Pennsylvania to complete additional training in Interventional Cardiology and Structural Heart Disease. To date, he has performed more than 10,000 diagnostic cardiac catheterizations and 4000 interventions. He has authored and co-authored multiple articles and book chapters on coronary interventions and transcatheter aortic valve replacement (TAVR). His research has been presented at the American College of Cardiology and at the Transcatheter Cardiovascular Therapeutics (TCT) Conference. He is a fellow of the American College of Cardiology and a fellow of the Society of Cardiovascular Angiography and Interventions (SCAI). He is an expert in transradial cardiac catheterization, complex coronary interventions, transcatheter aortic valve replacement (TAVR), and patent foramen ovale (PFO) closure.

He is board certified in internal medicine, echocardiography, cardiovascular disease, interventional cardiology, and nuclear cardiology. He currently serves as Chairman of Cardiology at Caremount/Optum, and Associate Director of the Seema Boesky Cath Lab at Northern Westchester Hospital.

Chairman of CardiologyCareMount / Optum NY
Associate Director, Cardiac Cath LabNorthern Westchester Hospital
Dr. A. Garvey Rene in the cardiac catheterization lab
Cardiac catheterization lab, Northwell Health

About

What Dr. Rene does, in plain terms.

Watch a short video: what happens during a heart catheterization and angioplasty performed through the wrist (radial artery) — the modern, minimally invasive approach used for most procedures today (Nucleus Medical Media).

Watch a short video: what happens during TAVR (transcatheter aortic valve replacement) — replacing a worn heart valve without open-heart surgery (Mayo Clinic).

Watch a short video: what happens during a transcatheter PFO closure — closing a small opening between the heart's upper chambers using a catheter, without open-heart surgery.

Hospital Affiliations: Northern Westchester Hospital, Lenox Hill Hospital, Danbury Hospital.

Dr. A. Garvey Rene at Northwell Health
Northwell Health

Clinical expertise: prevention, hypertension, cholesterol disorders, stable and acute coronary artery disease, valvular heart disease, vascular disease, pulmonary embolism, cardiogenic shock, cardiac critical care.

Technical expertise: transradial cardiac catheterization and interventions, atherectomy (laser, orbital, rotational), minimally invasive cardiac valve surgery, transcatheter aortic valve replacement, PFO closure.

Awards

Recognition over the years.
Business Council of Westchester 40 Under 40 Rising Star Recipient2018
Westchester Magazine Top Doctor2020–2026
Westchester Magazine Top Cardiologist2020–2026
NY Magazine Top Cardiologists2022–2026
American Heart Association Leader of Impact Nominee2025

Journal

Plain-language updates on new heart treatments and research, posted weekly.
October 19, 2026

Muscle is metabolic capital: why strength matters at every age

If one habit could support your metabolism, your independence, and how long you live, building and keeping lean muscle would be near the top of the list. Muscle is not just for strength or appearance. It is one of the most active and protective tissues in the body.

Muscle drives your resting metabolism. Roughly 60 to 75 percent of the calories you burn each day are used at rest, just to keep your heart beating, your brain working, and your cells running (Ravussin and Dulloo, 2022). The biggest factor in that resting burn is your fat-free mass, the lean tissue that includes muscle. It accounts for roughly 70 to 75 percent of the difference in resting metabolic rate between people (Stubbs et al., European Journal of Clinical Nutrition, 2018; Tran et al., Experimental & Molecular Medicine, 2022). Fat tissue contributes only about 3 to 5 percent of resting energy use (Ravussin and Dulloo, 2022). Build and keep muscle, and your baseline stays higher, even while you sleep. Lose it, and that baseline falls.

Muscle loss sneaks up on us. Muscle peaks around age 20 to 30. Between 40 and 70 it drops by roughly 8 percent per decade, and after 70 the losses speed up to nearly 10 percent per decade (Duan et al., Scientific Reports, 2025). This age-related loss, called sarcopenia, raises the risk of falls, fractures, disability, hospitalization, and death. Resistance (strength) training is the only non-drug approach shown to build and maintain muscle mass, strength, and power across the lifespan, and it is never too late to start (Fyfe et al., Sports Medicine, 2022).

Muscle and living longer. A meta-analysis of 56 studies and more than 42,000 people found that sarcopenia roughly doubled the risk of death (Xu et al., Gerontology, 2021). In older adults, functional sarcopenia was also linked to a higher risk of cardiovascular disease and death from any cause (Jeong et al., Scientific Reports, 2026). Any resistance training was associated with a 15 percent lower risk of death from any cause, 19 percent lower risk of cardiovascular death, and 14 percent lower risk of cancer death (Shailendra et al., American Journal of Preventive Medicine, 2022). A study following nearly 150,000 people for up to 30 years linked about 90 to 120 minutes of resistance training per week to a 13 percent lower risk of death, even after accounting for aerobic exercise (Zhang et al., British Journal of Sports Medicine, 2026). The lowest risk appears in people who do both strength and aerobic exercise (Gould et al., Cochrane Database of Systematic Reviews, 2022).

More is not always better. Benefits tend to level off at a moderate dose, roughly 60 to 120 minutes per week, and extra hours add little. The goal is consistency, not extremes.

More than calories. Resistance training also improves blood sugar control and insulin sensitivity, lowers blood pressure, strengthens bones, eases anxiety and depressive symptoms, and improves balance and function that help prevent falls (Fyfe et al., 2022; Gould et al., 2022).

Putting it into practice. Global guidelines recommend muscle-strengthening activity on at least two days per week, on top of regular aerobic activity. Train all the major muscle groups: legs, hips, back, chest, abdomen, shoulders, and arms. Use enough resistance to be challenging, whether that is bodyweight, bands, free weights, or machines. Pair it with walking, cycling, or swimming, and make protein and consistency a priority.

The bottom line. Lean muscle keeps your resting metabolism higher, protects your heart and bones, preserves your independence as you age, and is consistently linked to living longer. Strength training a couple of times a week is a modest habit with an outsized return.

This article is for general education and is not a substitute for personalized medical advice. Talk with your healthcare provider before beginning a new exercise program, especially if you have existing health conditions.

Older articles
September 13, 2026

Two big disappointments in heart disease prevention

Two closely watched studies reported out in the last few weeks, and both were letdowns — a reminder that a drug that looks great on paper doesn't always translate into fewer heart attacks and strokes.

Pelacarsen and Lp(a). Lp(a) is a cholesterol-like particle in the blood. Unlike regular cholesterol, it's almost entirely determined by genes — diet and exercise don't move it much — and roughly one in five people have levels high enough to raise their risk of heart attack and stroke. Until now, there's been no approved drug that directly lowers it. Pelacarsen, a once-monthly injection from Novartis, was the most advanced attempt: in a trial of over 8,300 people with known heart disease and high Lp(a), it lowered Lp(a) levels substantially. But on September 4, Novartis reported that the lower Lp(a) levels didn't translate into fewer heart attacks, strokes, or cardiovascular deaths compared with placebo. It's a real blow to a theory a lot of cardiologists believed in.

Milvexian and blood thinners after a heart attack. The second disappointment, from ESC Congress in Munich, involved milvexian — a new type of blood thinner designed to prevent a second heart attack or stroke without the bleeding risk of older blood thinners. In a trial of over 14,000 patients who'd recently had a heart attack or unstable angina, adding milvexian to standard treatment didn't reduce those events. The upside: it also didn't cause more bleeding, which keeps the door open for testing this type of drug in other situations.

What this means for patients. Neither of these changes anything about your current treatment. If you're on a statin, blood pressure medication, or a blood thinner your doctor prescribed, keep taking it — those remain the treatments proven to work. Lowering Lp(a) with medication isn't available yet despite the early hope, and this class of blood thinner isn't ready for routine post-heart-attack care either. Both trials are useful, though: they narrow down what actually works, which is how real progress in preventing heart disease gets made — one disappointing result at a time.

Get in touch

For patient care inquiries, please contact your CareMount/Optum NY or Northern Westchester Hospital office directly rather than through this site.

Connect on LinkedIn

CareMount / Optum NYChairman of Cardiology
Northern Westchester HospitalCardiac Cath Lab, Associate Director